Informa

2025³â 10¿ù 15-16ÀÏ
Marina Bay Sands, Singapore
RNA Leaders APAC Congress 2025
ÀÏÁ¤ : 2025³â 10¿ù 15-16ÀÏ
°³ÃÖ: Marina Bay Sands, Singapore

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ Àý´ÜÇü RNA Á¦Á¶¿Í Çõ½Å Çù¾÷À¸·ÎÀÇ ¸íÈ®ÇÑ °æ·Î

ÇÔ²², ¿¬°áµÇ¾î, °øµ¿À¸·Î RNA ÀǾàÀÇ º¯È­¸¦ ÃËÁø

RNA Leaders´Â À¯·´¡¤¹Ì±¹¿¡¼­ÀÇ Å« ¼º°ø¿¡ ÀÌ¾î ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡ ÁøÃâ

Choose your language
Traditional Chinese
Simplified Chinese
Japanese
English_

ÇöÀç °¡Àå ¿ì¼öÇÑ RNA ÀÎÀç·ÎºÎÅÍ ÆÄ¾Ç

RNA Leaders ÇÁ·Î±×·¥Àº Àå¼â RNA¡¤´Ü¼â RNA ½ºÆåÆ®·³ Àüü¿¡¼­ »ó¼¼ÇÑ °³¹ß Àü·«, µ¿Çâ, ±â¼ú ¿Ü¿¡ ´ÙÀ½ ÁßÁ¡ ºÐ¾ß¸¦ Æ÷ÇÔÇÑ °úÇÐ Æ®·¢ÀÌ Æ¯Â¡ÀÔ´Ï´Ù.

mRNA Vaccine & Therapeutics
mRNA ¹é½Å¡¤mRNA ÀǾà

  • Clinical data beyond infectious disease areas, such as oncology & rare diseases
    Á¾¾ç ¹× Èñ±ÍÁúȯ µî °¨¿°Áõ ÀÌ¿Ü ÀÓ»ó µ¥ÀÌÅÍ
  • Evaluate mRNA 2.0 modalities – circular RNAs, self-amplifying RNAs and self-replicating RNAs.
    mRNA 2.0 ¸ð´Þ¸®Æ¼ÀÇ Æò°¡ - ȯÇü RNA, ÀÚ±â ÁõÆø RNA, Àڱ⠺¹Á¦ RNA

Oligo-Based RNA Therapeutics
¿Ã¸®°í ±â¹Ý RNA ÀǾà

  • Development of ASOs and siRNA into the clinic
    ASO¡¤siRNAÀÇ ÀÓ»ó °³¹ß
  • Improve understanding of neurological cardiometabolic and rare diseases
    ½Å°æ°è, ½ÉÇ÷°ü´ë»ç°è, Èñ±ÍÁúȯÀÇ ÀÌÇØµµ Çâ»ó

Next-Gen RNA
Â÷¼¼´ë RNA

  • RNA editing and RNA cell therapy applications
    RNA ÆíÁý¡¤RNA ¼¼Æ÷Ä¡·áÀÇ ÀÀ¿ë
  • Evaluate POCs of regRNAs, tRNAs and other non-coding
    regRNA, tRNA, ±âŸ ºñÄÚµå RNA(ncRNA) POC Æò°¡
  • Re-emergence of microRNAs applications
    miRNA ÀÀ¿ëÀÇ ÀçµîÀå

Àü¿ë ³×Æ®¿öÅ©¿Í Çù¾÷ ±âȸ

°ø½Ä, ºñ°ø½Ä, ºñ±æ µ¥ ¾ø´Â ±âȸ

RNA Leaders¿¡¼­´Â ³×Æ®¿öÅ· ±âȸ¸¦ °­È­Çϰí, ¿ÃÇØ 10¿ù¿¡ Á¸Àç°¨À» ÃÖ´ëÇÑ ¹ßÈÖÇϱâ À§ÇØ ´Ù¾çÇÑ ¼Ò¼È ȯ°æÀ» Á¦°øÇÕ´Ï´Ù.

½º¸¶Æ®ÇÑ ³×Æ®¿öÅ© ±¸Ãà

Àü¿ë Ç÷§ÆûÀÎ PartneringOneÀ» ÀÌ¿ëÇϸé Àü·«Àû ÆÄÆ®³Ê ¹× ÁÖ¿ä ÀÇ»ç°áÁ¤ÀÚ¿Í ±³·ùÇϰí, ³×Æ®¿öÅ©¸¦ ¼Õ½±°Ô È®´ëÇÒ ¼ö ÀÖ½À´Ï´Ù.

¿µÇâ·Â ÀÖ´Â 1 on1 ¹ÌÆÃÀ» ¿¹¾àÇÏ¿© RNA LeadersÀÇ ¼º°ø »ç·Ê¿¡ µ¿ÂüÇϼ¼¿ä.

¾ÆÀ̵ð¾î¿Í ¼Ö·ç¼ÇÀÌ ¸¸³ª´Â Àå¼Ò

CEO °£ Ŭ·ÎÁîµå ±×·ì ȯ°æ¿¡¼­ ÁÖ¿ä ÆÄ¸¶ ¹× ¾÷°è Àü¹®°¡¿¡°Ô ¾×¼¼½ºÇϰí, ¹ÙÀÌ¿ÀÅ×Å©³î·¯ÁöÀÇ Æò°¡ ÇÁ·Î¼¼½º, IP ÀλçÀÌÆ®, ÀûÀýÇÑ ¾÷°è ÆÄÆ®³Ê µî ºñÁî´Ï½º¿¡ µµ¿òÀÌ µÇ´Â ½Ç¿ëÀû Àü·«À» ȹµæÇÒ ¼ö ÀÖ½À´Ï´Ù.

RNA »çÀ̾𽺿¡¼­ ¿µ°¨À» ÁÖ´Â ¿©¼º

RNA ºÐ¾ß ¿©¼ºµéÀÇ ¾÷ÀûÀ» ÃàÇÏÇϰí, ¾÷°èÀÇ Áøº¸¸¦ ÃßÁøÇÏ´Â À̳뺣ÀÌÅÍ ¹× µ¿·á·Î ±¸¼ºµÈ Áö¿ø Ä¿¹Â´ÏƼ¿Í ±³·ùÇÒ ¼ö ÀÖ½À´Ï´Ù.

RNA Leaders USA ... ¼öÄ¡

150+

Attendees

25+

Speakers

15+

Partnering Hours

Âü°¡ ¹æ¹ý

RNA Leaders´Â °¡Àå Çõ½ÅÀûÀÎ ±â¾÷°ú ÀûÀýÇÑ ÆÄÆ®³Ê¸¦ Çѵ¥ ¸ð¾Æ RNA °³¹ßÀÇ ¹Ì·¡¸¦ ÃßÁøÇÕ´Ï´Ù.

´ëÇ¥Àڷμ­ Âü°¡

2Àϰ£ »ý¸í°úÇÐ ºÐ¾ßÀÇ ¿ì¼öÇÑ ÀÎÀç¿ÍÀÇ À¯ÀÍÇÑ Á¦ÈÞ, Àü¹®°¡ ÆÐ³Î, ³×Æ®¿öÅ· ±âȸ¸¦ ÅëÇØ »õ·Î¿î µ¿·á¿Í ±³·ùÇÒ ¼ö ÀÖ½À´Ï´Ù.

±â¾÷ ÇÁ·¹Á¨Å×À̼Ç

ÀáÀçÀû ÆÄÆ®³ÊÀΠûÁß¿¡°Ô ±Í»çÀÇ ºê·¹ÀÌÅ©½º¸£¸¦ ¼Ò°³ÇÒ ±âȸÀÔ´Ï´Ù.

ÅõÀÚÀڷμ­ Âü°¡

ÀÚ°ÝÀ» °®Ãá ÅõÀÚÀÚ ¹× ¸®¼­Ä¡ ¾Ö³Î¸®½ºÆ®´Â RNA Leaders¿¡ Âü°¡Çϱâ À§ÇÑ ¹«·á µî·Ï ½ÅûÀÌ °¡´ÉÇÕ´Ï´Ù.

Marie Wikstrom Lindholm

SVP, Head of Molecular Design

Silence Therapeutics

"An interesting participant mix of big pharma, biotech, manufacturers & bio investors"

Melissa Moore

CSO

Moderna

"A really great place to connect with and network with my peers"

Dietrich A. Stephan

Chairman, Founder & CEO

Neubase Therapeutics

"One of the best conferences I have attended"

Marie Wikstrom Lindholm

SVP, Head of Molecular Design

Silence Therapeutics

"An interesting participant mix of big pharma, biotech, manufacturers & bio investors"

Melissa Moore

CSO

Moderna

"A really great place to connect with and network with my peers"

Dietrich A. Stephan

Chairman, Founder & CEO

Neubase Therapeutics

"One of the best conferences I have attended"

Marie Wikstrom Lindholm

SVP, Head of Molecular Design

Silence Therapeutics

"An interesting participant mix of big pharma, biotech, manufacturers & bio investors"

¾Æ½Ã¾ÆÅÂÆò¾çÀÇ RNA Leaders¿¡ °í±Þ ÀÇ»ç°áÁ¤ÀÚÀÇ °ü¿©

¾çÁúÀÇ ¸®µå ȹµæ, »ç°í ¸®´õÀÇ ¼Ò°³, ºê·£µåÀÇ °­È­ µî ¾î¶² ¿äûÀ̵ç Çù·ÂÇÏ¿© ºñÁî´Ï½º ¸ñÇ¥ÀÇ ´Þ¼º¿¡ µµ¿òÀÌ µÇ´Â Ä¿½ºÅÒ ½ºÆù¼­½Ê ±âȸ¸¦ Á¦¾ÈÇÕ´Ï´Ù.

ÀÚ¼¼ÇÑ »çÇ×Àº (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀ̼ÇÀ¸·Î ¹®ÀÇÇØÁֽñ⠹ٶø´Ï´Ù.